Verispan's Vector One: Higher than Average GERD Market Growth in HispanicsYARDLEY, Pa.--(BUSINESS WIRE)--Oct 11, 2007 - According to Verispan's Vector One(R): National, prescriptions within the gastroesophageal reflux disease (GERD) market have increased approximately 30% since 2002. Prescriptions have increased 37% for children age 4 or younger and 30% for children 5-11 years old. In this time period, Nexium and Prevacid experienced significant sales growth (146% and 70%, respectively).
Growth in this market among Hispanics was much more substantial. Verispan's Physician Drug & Diagnosis Audit reports that GERD visits have increased 70% since 2002 within the Hispanic community, with visits more than tripling for patients age 4 or younger. Visits by Hispanic patients ages 5-11 increased 60% in this time period, and the number of visits where a drug was issued nearly doubled for this sample.
Verispan's Direct-to-Consumer Advertising Audit reports that over $4 million was spent on advertising Nexium in the Spanish language media (Spanish language network TV and Spanish magazines) in the second quarter of 2007.
About Vector One(R)
Verispan's Vector One(R) delivers the True Measure of Healthcare, projecting both traditional prescription metrics and True Patient Measures at every level, from prescriber to nation. These precise measures are delivered in record time for sales representatives and managers, brand managers and market research departments to act and make a difference. Reports are available each week for data through the previous Friday, and monthly reports are available 10 to 14 days post-period, a clear improvement over competitors' delivery timelines.
Vector One's True Patient Measures utilize de-identified patient records to track patients across time, across pharmacies, across payers and across providers, and to uniquely pinpoint projected new patient starts, product switches, continuing patients, indication-specific utilization, co-morbid conditions, concomitant use, titration, persistency and a host of other powerful metrics at the individual prescriber level.
Since it includes actual dispensing data from a near census of the nation's pharmacies, the Vector One(R) projection methodology accounts for activity that is invisible to competing services, which only cover two-thirds of stores. Vector One(R) projects third-party, Medicaid and cash activity with unparalleled precision, resulting in greater accuracy at the prescriber level.
For more information about the Vector One(R) suite of data solutions or Verispan's longitudinal patient-centric database, please contact Chris Gilhorn at (800) 982-5613 or email@example.com.
About the Direct-to-Consumer Advertising Audit
Introduced in 1997, Verispan's Direct-to-Consumer Advertising Audit (DTCA) evaluates and measures the impact of DTC promotion of prescription products. DTCA measures consumer ad spending for prescription products and provides clients access to electronic images of consumer print campaigns.
For information about DTCA, please contact Heather Alba at (800) 982-5613 or firstname.lastname@example.org.
About the Physician Drug & Diagnosis Audit
The Physician Drug & Diagnosis Audit (PDDA) offers unique insights into physician-intended prescribing through quantitative drug and diagnosis analysis. PDDA provides national-level disease state and associated therapy data. PDDA targets office-based physicians representing 29 specialties across the United States who report all patient activity during one typical workday per month. This collection methodology produces a more robust data sample than similar diagnosis audit services. Collected information is projected by region and specialty to represent the activity of office-based physicians in the United States.
For additional information regarding PDDA, please contact Melissa Leonhauser at (800) 982-5613 or email@example.com.
Verispan: The True Measure of Healthcare
Verispan, a healthcare informatics joint venture of Quintiles Transnational Corp. and McKesson Corp., provides a broad array of information products and services to the healthcare industry, including sales targeting and compensation products; market research audits; healthcare profiles; comprehensive managed care offerings; data integration, warehousing and mining; data analysis and consulting; direct mail; list services; disease management studies; clinical trial investigator targeting and protocol recruitment evaluation; healthcare outcomes; and cost/benefit analyses, among many others. Verispan is also the nation's leading provider of patient-centric longitudinal data, with dozens of products used by clients spanning the industry.
Headquartered in Yardley, Pa., Verispan employs over 500 dedicated healthcare information professionals. The company's Web site is www.verispan.com.
Posted: October 2007
Recommended for you